Efficacy of Sitafloxacin for Mycoplasma genitalium in an Era of Increasing Antimicrobial Resistance
Open Access
- 22 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (12) , ofad590
Abstract
Antimicrobial resistance in Mycoplasma genitalium is rising globally and antimicrobial options are limited. We evaluated the efficacy of sitafloxacin regimens for macrolide-resistant M genitalium at Melbourne Sexual Health Centre, Australia, between January 2017 and February 2022. Before June 2017, patients received doxycycline followed by sitafloxacin; subsequently, patients received doxycycline followed by combined doxycycline + sitafloxacin. Of 229 patients treated with a sitafloxacin regimen, 80.6% experienced microbial cure. Sitafloxacin cured 94.2% of infections that had not previously failed moxifloxacin and 69.5% of infections that had; prior failure of moxifloxacin was associated with an 8-fold odds of sitafloxacin failure. There was no difference in cure between sequential monotherapy and combination therapy when patients were stratified by past failure of moxifloxacin (P > .05); however, small numbers limited comparisons. Sitafloxacin was well tolerated and still achieved 70% cure in patients in whom moxifloxacin had failed. These data highlight the benefit of incorporating relevant fluoroquinolone resistance markers into assays to assist clinical decision making.Keywords
Funding Information
- (NHMRC) Leadership Investigator (GNT1172900, GNT1173361)
- NHMRC Emerging Leadership Investigator (1172873)
This publication has 18 references indexed in Scilit:
- The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trialJournal of Infection and Chemotherapy, 2019
- Resistance-Guided Antimicrobial Therapy Using Doxycycline–Moxifloxacin and Doxycycline–2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and TolerabilityClinical Infectious Diseases, 2019
- Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trialInfection and Drug Resistance, 2019
- Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strainsPLOS ONE, 2018
- Outcomes of Resistance-guided Sequential Treatment ofMycoplasma genitaliumInfections: A Prospective EvaluationClinical Infectious Diseases, 2018
- New Horizons in Mycoplasma genitalium TreatmentThe Journal of Infectious Diseases, 2017
- In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae IsolatesMicrobial Drug Resistance, 2017
- Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complexJournal of Microbiology, Immunology and Infection, 2015
- Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritisJournal of Infection and Chemotherapy, 2013
- SitafloxacinDrugs, 2011